15.A host cell comprising an expression vector according to claim 13, wherein the FUT8 gene encoding alpha-1,6-fucosyltransferase has been inactivated in the host cell.

16.An antigen binding protein according to any of claims 1 to 6 or a humanised antibody according to any of claims 7 to 11 as produced by the host cell of claim 14 or 15.

17.A method of producing an antigen binding protein according to any of claims 1 to 6 or a humanised antibody according to any of claims 7 to 11, comprising a) culturing a host cell according to claim 14 under conditions suitable to express the antigen binding protein or antibody and b) isolating the antigen binding protein or antibody.

18. A method of producing a humanised antibody according to claim 10 or 11, comprising a) culturing a host cell according to claim 15 under conditions suitable to express the antigen binding protein or antibody, wherein the FUT8 gene encoding alpha-1,6-fucosyltransferase has been inactivated in the recombinant host cell, and b) isolating the antibody.

19.A pharmaceutical composition comprising a) an antigen binding protein according to any of claims 1 to 6 or an antibody according to any of claims 7 to 11, and b) a pharmaceutically acceptable carrier.

20.An antigen binding protein as defined in any of claims 1 to 6 or a humanised antibody as defined in any of claims 7 to 11, for use in therapy.

21.An antigen binding protein as defined in any of claims 1 to 6 or a humanised antibody as defined in any of claims 7 to 11 for use in the treatment of an autoimmune disease selected from the group consisting of psoriasis, Crohn's disease, rheumatoid arthritis, primary biliary cirrhosis, systemic lupus erythematosus (SLE), Sjogren's syndrome, multiple sclerosis, ulcerative colitis and autoimmune hepatitis; an infectious disease, an allergic disease or cancer.

22.Use of an antigen binding protein as defined in any of claims 1 to 6 or a humanised antibody as defined in any of claims 7 to 11 in the manufacture of a medicament for the treatment of an autoimmune disease selected from the group consisting of psoriasis, Crohn's disease, rheumatoid arthritis, primary biliary cirrhosis, systemic lupus erythematosus (SLE), Sjogren's syndrome, multiple sclerosis, ulcerative colitis and autoimmune hepatitis; an infectious disease, an allergic disease or cancer.